Sharing few educational slides from The Beckman Coulter Clinical Flow Cytometry Virtual Workshop that happened this past weekend 

Slides shared with permission
#hemepath #FlowCytometry #BeckmanCoulter
Opening remarks and what's new at Beckman Coulter Life Sciences 1/


Slides shared with permission
#hemepath #FlowCytometry #BeckmanCoulter
Opening remarks and what's new at Beckman Coulter Life Sciences 1/
It was interesting to learn about CD38 nanobody
The issue with daratumumab therapy is that it masks CD38 antigen- makes it harder to monitor CD38 in MRD
So CD38 nanobody (JK36) recognizes a cryptic epitope/ hidden regions in the CD38 protein that is not masked by anti-CD38Â 2/

The issue with daratumumab therapy is that it masks CD38 antigen- makes it harder to monitor CD38 in MRD
So CD38 nanobody (JK36) recognizes a cryptic epitope/ hidden regions in the CD38 protein that is not masked by anti-CD38Â 2/
Here is a link to our recent webinar "The Camelid-derived Nanobody JK36": https://beckman.wistia.com/medias/2qhfw3u95j  3/
Learning Session 1-The Healthy Immune System session (Dr. Lisa Holey, Clinical Solutions Manager, Beckman Coulter Life Sciences)Â 4/
Technical Session 2 - Plasma Cell Testing for Myeloma MRD Analysis (Mike Sutter, MT, SH, ICEE, Technical Specialist, Hematology/Flow Cytometry, Pathology Consultants)Â
Â
As chart
shows, hight level of MRD tumor cells relapse quicky 6/
Â
As chart
